An announcement from Invion ( (AU:IVX) ) is now available.
Invion Limited has successfully completed a $2 million share placement to accelerate its clinical programs, including a Phase I/II trial for skin cancer and an anogenital trial in collaboration with the Peter MacCallum Cancer Centre. The funds will also support general working capital and potentially enable orphan drug designation in the US for the anogenital trial, offering a faster commercialization path for Photosoft™. The placement was met with strong demand, highlighting investor confidence in Invion’s strategic milestones, including updates on glioblastoma, oesophageal cancer, and HPV studies.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on the development of Photosoft™, a potential treatment for various cancers. The company is engaged in advancing research and development in cancer treatment, with a market focus on rare diseases and partnerships to fund specific studies.
Average Trading Volume: 110
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.13M
For detailed information about IVX stock, go to TipRanks’ Stock Analysis page.